Preface. Pediatric and Adolescent Psychopharmacology: The Past, the Present, and the Future

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages

  Greydanus, Donald E ^a   Patel, Dilip R ^b   Feucht, Cynthia ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b Borgess Ambulatory Care   (United States)

^c FERRIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; FLUOXETINE; IMIPRAMINE; IPRONIAZID; LITHIUM;

ADDICTION; ADOLESCENT; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CHILD PSYCHIATRY; DIET SUPPLEMENTATION; EDITORIAL; EVIDENCE BASED MEDICINE; FAMILY THERAPY; HUMAN; MEDICAL HISTORY; MEDICAL RESEARCH; MENTAL DISEASE; MENTAL HEALTH; PSYCHOPHARMACOLOGY; PSYCHOSIS; PUBLICATION; PUBLISHING;

ADOLESCENT; ADOLESCENT PSYCHIATRY; CHILD; CHILD PSYCHIATRY; FORECASTING; HISTORY, 15TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HISTORY, ANCIENT; HUMANS; PSYCHOPHARMACOLOGY;

EID: 79251583458     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.11.005     Document Type: Editorial

References (75)

1. Magner L.N. A history of the life sciences 2002, Marcel Dekker, Inc, New York, p. 502. 3rd edition.
2. Greydanus D.E., Patel D.R. Sports doping in athletes. Pediatr Clin North Am 2010, 57(3):729-750.
3. Grollman A.P. Alternative medicine: the importance of evidence in medicine and medical evidence. Is there wheat among the chaff?. Acad Med 2001, 76(3):221-223.
4. Porter R. The greatest benefit to mankind: a medical history of humanity 1998, WW Norton & Co, New York.
5. Scholl R. Der Papyrus Ebers. Die grösste Buchrolle zur Heilkunde Altägyptens (Schriften aus der Universitätsbibliothek 7) 2002, Universitat von Leipzig, Leipzig, Germany.
6. Wheelwright P. Aristotle 1951, The Odyssey Press, New York, p. 68.
7. Greydanus D.E., Geller B. Masturbation: historical perspective. NY State Med 1980, 80:1892-1896.
8. Von Rosenstein R. The diseases of children and their remedies 1776, T. Cadell, London (England), p. 31.
9. Scudder N.J.M. The eclectic practice of diseases of children 1869, American Publishing Co, Cincinnati, p. 19.
10. Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine 1892, D. Appleton and Company, New York, p. 1079.
11. Pratt H.D. Normal psychological development. Behaviorial pediatrics 2006, 5-36. iUniverse, Inc, New York, chapter 1. 2nd edition. D.E. Greydanus, D.R. Patel, H.D. Pratt (Eds.).
12. Greydanus D.E., Patel D.R., Pratt H.D. ADHD across the lifespan. Dis Mon 2007, 53(2):65-132.
13. Still G. The Coulstonian lectures on some abnormal physical conditions in children. Lecture 1. Lancet 1902, 1:1008-1012.
14. Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry 1937, 94:577-585.
15. Molitch M., Eccles A.K. The effect of Benzedrine sulfate on the intelligence scores of children. Am J Psychiatry 1937, 94:577-585.
16. Eberle J. Treatise on the diseases and physical education of children 1837, Grigg and Elliot, Philadelphia, p. 489.
17. Radbill S.X. The first treatise on pediatrics. Am J Dis Child 1971, 122:369-376.
18. Haggerty R. Preface. Behavioral pediatrics 1992, 1-490. Springer-Verlag, New York. D.E. Greydanus, M. Wolraich (Eds.).
19. López-Muňoz F., Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des 2009, 15:1563-1586.
20. Delini-Stula A. Discovery of the tricyclic antidepressants. Pharm Unserer Zeit 2008, 37:194-197.
21. Knobel M., Wolman M., Mason A. Hyperkinesis and organicity in children. Arch Gen Psychiatry 1959, 1(3):310-321.
22. Musto D.F. History of child psychiatry. Child and adolescent psychiatry. A comprehensive text 2002, Lippincott Williams & Wilkins, Philadelphia, p. 1448-1449, chapter 133. 3rd edition. M. Lewis (Ed.).
23. Friedman S.B. Introduction: behavioral pediatrics. Pediatr Clin North Am 1975, 22:55.
24. Accardo P.J. The father of developmental pediatrics: Arnold J. Capute, MD, MPH (1923-2003). J Child Neurol 2004, 19(12):978-981.
25. Gallagher J.R. Medical care of the adolescent 1960, Appleton-Century-Crofts, New York. 1st edition.
26. Werry J.S., Aman M.G. Preface to the first edition. Practitioner's guide to psychoactive drugs for children and adolescents 1999, Plenum Medical Book Company, New York, p. xi.
27. Greydanus D.E., Patel D.R. The role of pharmaceutical influence in education and research: the clinician's response. Asian J Paediatr Pract 2006, 9:35-41.
28. Tan J.O., Koeich M. The ethics of psychopharmacological research in legal minors. Child Adolesc Psychiatr Ment Health 2008, 2:39-43.
29. Vitiello B., Heiligenstein J.H., Riddle M.A., et al. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration. Biol Psychiatry 2004, 56:3-9.
30. MTA Study Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 1999, 56:1073-1086.
31. March J. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004, 292:807-820.
32. Fournier J.C., DeRubeis R.J., Hollon S.D., et al. Antidepressant drug effect and depression severity. A patient level metaanalysis. JAMA 2010, 303:47-53.
33. Begley S. The depressing news about antidepressants. Newsweek February 8, 2010 p. 35-41.
34. Whalen C.R., Henker B. Therapies for hyperactive children: comparisons, combinations, and compromises. J Consult Clin Psychol 1991, 59:126-137.
35. Pelham W., Fabriano G.A. Behavior modification. Child Adolesc Psychiatr Clin North Am 2000, 9(3):671-688.
36. Fergusson D., Doucette S., Granley-Glass K., et al. The association between suicide attempts and SSRIs: a systemic review of 677 randomized controlled trials representing 85,470 participants. BMJ 2005, 330:396-399.
37. Kadison R. Getting an edge-use of stimulants and antidepressants in college. N Engl J Med 2005, 353:1089-1091.
38. Nisson S.E. ADHD drugs and cardiovascular risks. N Engl J Med 2006, 354(14):1445-1448.
39. Hechtman L., Greenfield B. Long-term use of stimulant use in children with ADHD: safety, efficacy, and long-term outcome. Paediatr Drugs 2003, 5(12):787-794.
40. MTA Study Group. FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse. JAMA 2009, 302:833-834.
41. Wilens T.E. Combined pharmacotherapy in pediatric psychopharmacology: friend or foe?. J Child Adolesc Psychopharmacol 2009, 19(5):483-484.
42. Spencer T.J. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs 2009, 23(Suppl 1):9-20.
43. Spencer T.J. Toward a new understanding of attention-deficit hyperactivity disorder: advances in research and treatment. CNS Drugs 2009, 23(Suppl 1):5-8.
44. Wink L.K., Plawecki M.H., Erickson C.A., et al. Emerging drugs for the treatment of symptoms with autism spectrum disorder. Exp Opin Emerg Drugs 2010, 15:481-494.
45. Bassarath L. Medication strategies in childhood aggression: a review. Can J Psychiatry 2003, 48(6):367-373.
46. Hamrin V., Lennaco J.D. Psychopharmacology of pediatric bipolar disorder. Exp Rev Neurother 2010, 10(7):1053-1088.
47. Nevels R.M., Dehon E.E., Alexander K., et al. Psychopharmacology of aggression in children and adolescents with primary neuropsychiatric disorders: a review of current and potentially promising treatment options. Exp Clin Psychopharmacol 2010, 18(2):184-201.
48. Steiner H., Karnik N.S. Integrated treatment of aggression in the context of ADHD in children refractory to stimulant monotherapy: a window into the future of child psychopharmacology. Am J Psychiatry 2009, 166(12):1315-1317.
49. Kölch M., Ludolph A.G., Plener P.L., et al. Safeguarding children's rights in psychopharmacological research: ethical and legal issues. Curr Pharm Des 2010, 16(22):2398-2406.
50. Greydanus D.E., Feucht C. Performance-enhancing drugs and supplements 2009, McGraw-Hill Medical, New York, p. 63-77, chapter 7. D.R. Pediatric practice: sports medicine. Patel, D.E. Greydanus, R.J. Baker (Eds.).
51. Giedd J.N. The teen brain: insights from neuroimaging. J Adolesc Health 2008, 42(4):335-343.
52. Waber D.P. The NIH MRI study of normal brain development: performance of a population-based sample of healthy children aged 6 to 18 years on a neuropsychological battery. J Int Neuropsycholog Soc 2007, 13:1-18.
53. DeVeaugh-Geiss J., March J., Shapiro M., et al. Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psychiatry 2006, 45:261-270.
54. Schuen J.N. Sleep disorders in the adolescent. Essential adolescent medicine 2006, 281-297. McGraw-Hill Medical Publishing Div, New York, chapter 14. D.E. Greydanus, D.R. Patel, H.D. Pratt (Eds.).
55. Wolfson A.R. Adolescents and emerging adults' sleep patterns: new developments. J Adolesc Health 2010, 46:97-99.
56. McCrae C.S., Taylor D.J., Smith M.T., et al. The future of behavioral sleep medicine. Behav Sleep Med 2010, 8(2):74-89.
57. Baldwin C.M., Ervin A.M., Mays M.Z., et al. Sleep disturbances, quality of life, and ethnicity: the Sleep Heart Health Study. J Clin Sleep Med 2010, 6(2):176-183.
58. Glickman G. Circadian rhythms and sleep in children with autism. Neurosci Biobehav Rev 2010, 34(5):755-768.
59. Toriello J. The Human Genome Project 2003, Rosen Publishing Co, New York, p. 64.
60. Dick D.M., Riley B., Kendler M.S. Nature and nurture in neuropsychiatric genetics: where do we stand?. Dialogues Clin Neurosci 2010, 12(4):7-23.
61. Duan J., Sanders A.R., Gejman P.V. Genome-wide approaches to schizophrenia. Brain Res Bull 2010, 83:93-102.
62. Gunter T.D., Vaughn M.G., Philibert R.A. Behavioral genetics in antisocial spectrum disorders and psychopathology: a review of the recent literature. Behav Sci Law 2010, 28(2):148-173.
63. Purper-Ouakil D., Lepagnol-Bestel A.M., Grosbellet E., et al. Neurobiology of attention deficit hyperactivity disorder. Med Sci (Paris) 2010, 26:487-496.
64. Kendler K.S. Genetic and environmental pathways to suicidal behavior: reflections of a genetic epidemiologist. Eur Psychiatry 2010, 25(5):300-303.
65. Casey B.J., Soliman F., Bath K.G., et al. Imaging genetics and development: challenges and promises. Hum Brain Mapp 2010, 31(6):838-851.
66. Nestler E.J. Psychogenomics: opportunities to understand addiction. J Neuro Sci 2001, 21:8324-8327.
67. Kriechman A., Salvador M., Adelsheim S. Expanding the vision: the strengths-based, community-oriented child and adolescent psychiatrist working in schools. Child Adolesc Psychiatr Clin North Am 2010, 19(1):149-162.
68. Staller J.A. Service delivery in child psychiatry: provider shortage isn't the only problem. Clin Child Psychol Psychiatry 2008, 13(1):171-178.
69. Kim W. Recruitment. Child Adolesc Psychiatr Clin North Am 2007, 16(1):45-54.
70. Thomas C.R. Holzer CE 3rd. The continuing shortage of child and adolescent psychiatrists. J Am Acad Child Adolesc Psychiatry 2006, 45(9):1023-1031.
71. Kim W.J. American Academy of Child and Adolescent Psychiatry Task Force on Workforce Needs. Child and adolescent psychiatry workforce: a critical shortage and national challenge. Acad Psychiatry 2003, 27(4):277-282.
72. Berkovitz I.H., Sinclair E. Training programs in school consultation. Child Adolesc Psychiatr Clin North Am 2001, 10(1):83-92.
73. Paula C.S., Nakamura E., Wissow L., et al. Primary care and children's mental health in Brazil. Acad Pediatr 2009, 9(4):249-255.
74. Reeves G., Anthony B. Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders: implications of access, effectiveness, and contextual treatment. Paediatr Drugs 2009, 11(3):165-169.
75. Sarvet B.D., Wegner L. Developing effective child psychiatry collaboration with primary care: leadership and management strategies. Child Adolesc Psychiatr Clin North Am 2010, 19(1):139-148.